Search research articles
Contact Us
Filters
Showing results (41-50 of 224) with videos related to
Page
of 23
Sort By:
Future Oncology (London, England)
|
January 31, 2026
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia
Mazyar Shadman, Asher Chanan-Khan, David Campbell, et al.
American Journal of Hematology
|
November 22, 2021
Heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies
Chaitra Ujjani, Alexander L Greninger, Mazyar Shadman, et al.
Blood Advances
|
October 8, 2020
Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy
Victor A Chow, Ajay K Gopal, Jordan Gauthier, et al.
Advances in Therapy
|
June 11, 2026
Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up
Mazyar Shadman, Talha Munir, Sheng Xu, et al.
American Journal of Hematology
|
December 20, 2021
A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia
Matthew S Davids, Mazyar Shadman, Sameer A Parikh, et al.
Leukemia & Lymphoma
|
February 10, 2010
OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia
Anjali S Advani, Kathleen Lim, Sarah Gibson, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 6, 2017
Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy
Prathima Reddy, Sandra Kanan, Andrew Cowan, et al.
Journal of Clinical Pathology
|
August 25, 2025
Digital pathology and image analysis of p53 biomarker in lymphomas using two algorithms: correlation with genotype and visual inspection
Anisha Naik, Aarti Kanzaria, Xueyan Chen, et al.
Current Medical Research and Opinion
|
February 13, 2026
Zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: health-related quality of life in a subgroup of Chinese patients in the ALPINE trial
Constantine S Tam, Mazyar Shadman, Shin Yeu Ong, et al.
Leukemia & Lymphoma
|
July 3, 2015
Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission
Mazyar Shadman, Ajay K Gopal, Britt Kammerer, et al.
Page
of 23
Search research articles
Search
Showing results (41-50 of 224) with videos related to
Sort By:
Page
of 23
Future Oncology (London, England)
|
January 31, 2026
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia
Mazyar Shadman, Asher Chanan-Khan, David Campbell, et al.
American Journal of Hematology
|
November 22, 2021
Heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies
Chaitra Ujjani, Alexander L Greninger, Mazyar Shadman, et al.
Blood Advances
|
October 8, 2020
Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy
Victor A Chow, Ajay K Gopal, Jordan Gauthier, et al.
Advances in Therapy
|
June 11, 2026
Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up
Mazyar Shadman, Talha Munir, Sheng Xu, et al.
American Journal of Hematology
|
December 20, 2021
A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia
Matthew S Davids, Mazyar Shadman, Sameer A Parikh, et al.
Leukemia & Lymphoma
|
February 10, 2010
OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia
Anjali S Advani, Kathleen Lim, Sarah Gibson, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 6, 2017
Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy
Prathima Reddy, Sandra Kanan, Andrew Cowan, et al.
Journal of Clinical Pathology
|
August 25, 2025
Digital pathology and image analysis of p53 biomarker in lymphomas using two algorithms: correlation with genotype and visual inspection
Anisha Naik, Aarti Kanzaria, Xueyan Chen, et al.
Current Medical Research and Opinion
|
February 13, 2026
Zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: health-related quality of life in a subgroup of Chinese patients in the ALPINE trial
Constantine S Tam, Mazyar Shadman, Shin Yeu Ong, et al.
Leukemia & Lymphoma
|
July 3, 2015
Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission
Mazyar Shadman, Ajay K Gopal, Britt Kammerer, et al.
Page
of 23